Skip to main content
PLOS One logoLink to PLOS One
. 2024 Jun 11;19(6):e0298233. doi: 10.1371/journal.pone.0298233

Barriers and facilitators to perioperative smoking cessation: A scoping review

Sandra Ofori 1,*, Daniel Rayner 2, David Mikhail 3, Flavia K Borges 1, Maura M Marcucci 1, David Conen 1, Lawrence Mbuagbaw 4, P J Devereaux 1
Editor: Silvia Fiorelli5
PMCID: PMC11166293  PMID: 38861527

Abstract

Objective

Smoking cessation interventions are underutilized in the surgical setting. We aimed to systematically identify the barriers and facilitators to smoking cessation in the surgical setting.

Methods

Following the Joanna Briggs Institute (JBI) framework for scoping reviews, we searched 5 databases (MEDLINE, Embase, Cochrane CENTRAL, CINAHL, and PsycINFO) for quantitative or qualitative studies published in English (since 2000) evaluating barriers and facilitators to perioperative smoking cessation interventions. Data were analyzed using thematic analysis and mapped to the theoretical domains framework (TDF).

Results

From 31 studies, we identified 23 unique barriers and 13 facilitators mapped to 11 of the 14 TDF domains. The barriers were within the domains of knowledge (e.g., inadequate knowledge of smoking cessation interventions) in 23 (74.2%) studies; environmental context and resources (e.g., lack of time to deliver smoking cessation interventions) in 19 (61.3%) studies; beliefs about capabilities (e.g., belief that patients are nervous about surgery/diagnosis) in 14 (45.2%) studies; and social/professional role and identity (e.g., surgeons do not believe it is their role to provide smoking cessation interventions) in 8 (25.8%) studies. Facilitators were mainly within the domains of environmental context and resources (e.g., provision of quit smoking advice as routine surgical care) in 15 (48.4%) studies, reinforcement (e.g., surgery itself as a motivator to kickstart quit attempts) in 8 (25.8%) studies, and skills (e.g., smoking cessation training and awareness of guidelines) in 5 (16.2%) studies.

Conclusion

The identified barriers and facilitators are actionable targets for future studies aimed at translating evidence informed smoking cessation interventions into practice in perioperative settings. More research is needed to evaluate how targeting these barriers and facilitators will impact smoking outcomes.

Background

Annually, over 300 million major surgical procedures are undertaken globally [1]. Surgery is an important point of contact between patients and the health care system and is an excellent opportunity to address the health needs of patients, as they are focused on their health during this time [2,3]. In North America, the prevalence of smoking among surgical patients is between 14% and 27% [46] compared to 13% to 14% of the general population [7]. Smoking is a leading cause of mortality and is associated with the risk of cardiac, infectious, and pulmonary complications, and delayed wound healing after surgery [8,9].

Smoking cessation involves the use of evidence-based pharmacotherapy and behavioral counseling [1012]. Few surgical patients receive these interventions despite perioperative guidelines recommending them [1315]. In an analysis from the VISION study, a large prospective cohort study of a representative sample of 40,004 patients aged ≥45 years who underwent major noncardiac surgery across 28 centers in 14 countries, we found that, among the 5480 (13.7%) who were smoking in the 4 weeks preceding their surgery, only 2.4% received any smoking cessation pharmacotherapies before surgery and 6.5% after surgery. Over 50% of the smokers resumed smoking after surgery, majority within 14 days [16].

Smoking cessation is complex and requires individual and system-led behavior changes [17,18]. Several studies have investigated possible barriers and facilitators in the implementation of perioperative smoking cessation interventions. Many of them from the perspective of specific subgroups of perioperative care providers like sub-specialty surgeons or nurses, limiting the interpretation of the results in a broader context [1923].

The theoretical domains framework (TDF) is an evidence-based and comprehensive framework that can help understand the determinants of behavior change [24]. The TDF provides a structured approach to understanding the various factors that influence smoking behavior, including attitudes, beliefs, social influences, and environmental factors. The TDF offers a framework to develop more effective smoking cessation programs that consider these factors to improve cessation rates and reduce the harm caused by smoking [25]. Previous studies have utilized the TDF framework to identify key factors affecting smoking cessation in various groups. Campbell et al. found that existing smoking cessation methods for pregnant women don’t sufficiently address social network influences, a major barrier [26]. Huddlestone et al. identified time constraints as the main obstacle for smoking cessation in mental health settings, with effective support materials being the most helpful enabler [27].

To our knowledge, no review has evaluated the barriers and facilitators of smoking cessation in the surgical setting. Therefore, we conducted scoping review of the existing literature to identify the barriers and facilitators to smoking cessation in the surgical setting, involving patients and the healthcare system and providers, and to organize this evidence into a theoretical-domains framework (TDF).

Review Objective: The objective of this scoping review was to summarize the quantitative and qualitative literature on the barriers and facilitators of smoking cessation among adults undergoing surgery.

Methods

We conducted this scoping review according to the Joanna Briggs Institute (JBI) guidelines [28]. This method permits inclusion of all relevant literature and focuses on collating and summarizing the evidence. The manuscript was prepared according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses Extension for Scoping Reviews (PRISMA-ScR) guidelines (S1 Table) [29]. We did not register the protocol for this scoping review.

Search strategy

We consulted a health sciences librarian with expertise in quantitative and qualitative methods, and developed a search strategy for MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, and PsycINFO databases using keywords and MeSH terms (S2 Table).

The search was restricted to English language articles published in 2000 or later. We also manually-searched all reference lists of included studies to identify additional studies of relevance. We also screened systematic reviews for individual studies that met the eligibility criteria. The final searches were conducted on 11 August 2022.

Eligibility criteria

We considered all published studies (quantitative and qualitative) involving adults (aged 18 or older) who smoke undergoing surgery or involving health care professionals who care for them. We included studies published in 2000 or later, in English, detailing barriers and facilitators of perioperative smoking cessation interventions from the perspective of health care providers or patients, with no geographic limitations. We included RCTs, prospective and retrospective cohort studies, cross-sectional studies, qualitative studies, and mixed-methods studies. We excluded studies not involving our population of interest, reviews, or editorials, and theses and conference abstracts that were not published in full.

Study selection

Two reviewers independently conducted a pilot screening of 10 randomly chosen references to ensure consistent application of our eligibility criteria. Following a consensus meeting and final adjustments, the remaining titles and abstracts were screened independently by two reviewers on Covidence (Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. Available at www.covidence.org). Potentially relevant full text articles were independently assessed by two reviewers, and disagreements were resolved through discussion or by a third reviewer. We recorded the reasons for exclusion of full-text articles (S1 File).

Data extraction

Two reviewers independently extracted data using a pre- piloted Excel form, including participant details, study methods, and key findings. The form was tested using two articles independently by two reviewers and revised in a meeting. Disagreements were resolved through discussion or third-party review.

Appraisal of study reporting quality

Two reviewers independently, performed quality appraisal and reporting of methodological quality of the included studies using the Mixed Methods Appraisal Tool (MMAT). The MMAT facilitates the evaluation of the methodological quality of studies included in a review when it includes qualitative research, randomized controlled trials, non-randomized studies, quantitative descriptive studies, and mixed methods studies [30]. There is no clearly defined scoring system with this tool, and we chose to report the final reporting quality as the percentage of the number of reporting items divided by the number of total items evaluated. We considered scores <60% as low, 60–80% as moderate or >80% as high quality. Disagreements were resolved by discussion or by a third reviewer.

Data analysis and presentation

Theoretical framework

We used the TDF. This is a determinant framework that is used to describe factors (barriers or facilitators) that can influence behavior change. The TDF builds on 128 behavior change constructs found in 33 behavior change theories. These constructs are categorized into 14 theoretical domains; knowledge, skills, memory, attention and decision processes, behavioral regulation, social/professional role and identity, beliefs about capabilities, optimism, beliefs about consequences, intentions, goals, reinforcement, emotion, environmental context and resources, and social influences [24].

Data synthesis

Two reviewers conducted thematic analysis to identify common ideas and patterns from the articles. They grouped these into subthemes and broad themes, with disagreements resolved by discussion. We extracted data on what participants considered as barriers and facilitators to smoking cessation and we present the number of participants who express these within each study as numbers and percentages. We provide a descriptive summary of the number of identified articles that report barriers or facilitators from healthcare providers and patients’ perspectives. We mapped all identified themes into the TDF domains and provide a descriptive summary highlighting the most frequent domains.

Ethics and dissemination

Our study did not require ethics approval as we collected publicly available data.

Results

Description of studies

Our database search yielded 6,962 publications. We screened 5,771 titles and abstracts after we removed duplicates and included 122 articles for full text review. Thirty-one articles met the eligibility criteria to be included in this review (Fig 1).

Fig 1. PRISMA flowchart.

Fig 1

The 31 studies were published between 2000 and 2022. There were 20 cross-sectional surveys, 2 randomized controlled trials (RCTs) that included a qualitative sub-analysis of barriers and facilitators, 4 qualitative and 5 mixed methods studies. Of the 31 studies, 12 included patients [3142], 6 included surgeons [4348], 5 included nurses [4453], 2 included anesthesia providers [22,54], 5 included a mix of health care providers (HCPs) including primary care physicians, nurses, anesthesiologists, and surgeons [19,23,5557], and 1 recruited surgical residency program directors [58]. Overall, 11,871 participants (10,407 HCPs, and 1,464 patients) were recruited across the 31 included studies (Table 1). Of all the included studies, only one was theory based. The authors cited that they were guided by “social cognitive theory and the conflict theory of decision making” [41].

Table 1. Study characteristics.

Author/Year Country Study design Participants Sample size
Crews 2008 [43] USA Cross-sectional survey Oral and maxillofacial surgeons 2740
Taniguchi 2011[50] Japan Cross-sectional survey Nurses 2215
Yao 2009 [48] China Cross-sectional survey Male surgeons 823
Schultz 2014 [58] USA Cross-sectional survey Anaesthesiology residency program directors and residents 528
Smeds 2017 [34] USA Cross-sectional survey Vascular surgery patients 490
Shi 2010 [3] China Cross-sectional survey Anaesthesiologists 482
Houghton 2008 [49] USA Cross-sectional survey Certified registered nurse anaesthetists 439
Yankie 2006 [51] USA Cross-sectional survey Certified registered nurse anaesthetists 271
Yu 2013 [37] China Cross-sectional survey Adults scheduled for elective non-cardiovascular surgery 227
Gay-Escoda 2012 [44] Spain Cross-sectional survey Oral surgeons 224
Marrufo 2019 [45] USA Cross-sectional survey Thoracic surgeons 200
Webb 2013 [36] Australia Cross-sectional survey Current smokers and those who reported quitting smoking for surgery planning to undergo surgery 177
Newhall 2017 [31] USA Pilot, multi-center, cluster RCT Adult smokers with PAD 156
Bottorff 2016 [40] Canada Cross-sectional surveys and interviews Smokers undergoing elective surgery 150
Saddichha 2010 [47] India Cross-sectional survey Dental surgeons 100
Owen 2007 [46] UK Cross-sectional survey Non-vascular surgeons 83
Shannon-Cain 2002 [33] USA Cross-sectional survey Smokers undergoing any elective outpatient surgical procedure 81
Rajae 2019 [32] USA Parallel group RCT Patients with peripheral arterial and aneurysmal disease 59
Van Slyke 2017 [35] Canada Cross-sectional cohort Cosmetic surgery patients 47
Rosvall 2017 [53] Sweden Mixed methods questionnaires and semi-structured interviews Surgical nurses 47
Jose 2020 [52] USA Mixed methods Focus groups Perioperative registered nurses 39
Farley 2016 [38] UK Qualitative semi-structured interview Surgical lung cancer patients 22
McDonnell 2014 [41] USA Mixed methods prospective, one-group repeated measures design with questionnaires and exit interviews Patients scheduled for surgery for a suspicious thoracic mass or known cancer and family members 16
McDonnell 2016 [42] USA Mixed methods prospective, one-group repeated measures design with questionnaires and exit interviews Patients scheduled for surgery for a suspicious thoracic mass or known cancer and family members 16
Kai 2008 [22] Japan Cross-sectional survey Anaesthesiologists and thoracic surgeons 1083 (542 anaesthetists; 541 surgeons)
Warner 2004 [20] USA Cross-sectional survey Anaesthesiologists and general surgeons 335 Anaesthesiologists, 359 general surgeons
Karabeyoglu 2014 [55] Turkey Cross-sectional survey Anaesthesiologists and general surgeons 274 (108 anaesthesiologists, 93 general surgeons, 41 anaesthesiology residents, 32 general surgery residents)
Vick 2011 [19] USA Cross-sectional survey Surgeons and anaesthesia providers, including both anaesthesiologists and nurse anaesthetists 92 (55 surgeons, 22 anaesthesia providers, 15 primary care providers)
Luxton 2019 [23] UK Qualitative One-on-one, semi-structured interviews Cardiothoracic surgeons, anaesthetists, nurses, and physiotherapists 52 (15 cardiothoracic surgeons, 15 consultant anaesthetists, 11 nurses, 11 physiotherapists)
Warner 2008 [39] USA Qualitative semi-structured interview Smoking surgical patients, staff anaesthesiologists and surgeons 29 (19 cigarette smokers, 5 anaesthesiologists, 5 surgeons)
Newhall 2016 [57] USA Qualitative Focus groups Vascular Quality Initiative representative, Tobacco cessation counsellor, Tobacco Quit Line representative, Vascular surgeons, Vascular surgery patients 15 (2 tobacco cessation counsellors, 1 Quit Line representative, 1 Vascular Quality Initiative leader, 7 vascular surgeons, 4 patients)

UK- United Kingdom; USA- United States of America; RCT- Randomized controlled trial.

Reporting quality

Of the 31 articles, 10 (32.3%) articles scored >80% for reporting quality and 21 (67.7%) scored 60–80%. None scored <60%. The average reporting quality of the 33 articles was a mean of 85% ± 11% (S3 Table).

Identified barriers and facilitators

Our review identified 23 barriers and 13 facilitators to perioperative smoking cessation mapped to 11 of the 14 TDF domains (Table 2 and Fig 2). The most frequent domains for identified barriers and facilitators were the environmental context and resources (31 studies, 3 barriers, 7 facilitators), knowledge (23 studies, 4 barriers, no facilitators), beliefs about capabilities (15 studies, 3 barriers, 1 facilitator), and social/professional role and identity (9 studies, 2 barriers, 1 facilitator) domains (S1 Fig).

Table 2. Themes and sub-themes inductively generated for each TDF domain.

DOMAIN & THEMES SUB-THEME
BARRIER/FACILITATOR
PERSPECTIVE
N = number of studies
Surgeons Anaesthesia providers Nurses Mixed healthcare provider Patients Other Total
1. Environmental context and resources (n = 31 studies)
Time constraints Barrier: lack of time, limited time for face-to-face visits and counselling 3 2 2 3 0 1 11
Availability of smoking cessation support services Barrier: lack of smoking cessation program in the hospital 1 0 0 1 0 1 3
Cost constraints Barrier: cost of medications, lack of reimbursement for smoking cessation service provided 1 0 0 1 0 0 2
Integration of smoking cessation into perioperative workflow Facilitator: seamless integration to link patients with external resources 0 0 0 1 1 0 2
Person/environment interaction Facilitator: Sensitive and proactive approach to smoking cessation by healthcare provider 0 0 0 2 1 0 3
Facilitator: concurrent receipt of smoking cessation advise from friends and family 0 0 0 0 1 0 1
Facilitator: providers’ positive attitude towards smoking cessation counselling 0 0 1 0 0 0 1
Facilitator: physicians and/or surgeons should provide advice to quit smoking as part of routine care 0 0 0 1 4 0 5
Facilitator: utilization of multiple media sources to provide smoking cessation advise 0 0 0 1 1 0 2
Facilitator: individualization and patient specific timing of the approach to smoking cessation 0 0 0 1 0 0 1
2. Knowledge (n = 23 studies)
Knowledge of benefits Barrier: perceived health benefits of smoking 0 0 0 0 2 0 2
Lack of adequate knowledge of smoking cessation support Barrier: knowledge of available smoking cessation interventions 2 2 1 4 1 0 10
Barrier: limited knowledge of smoking cessation counselling 0 2 0 3 0 0 5
Barrier: perceived lack of efficacy of smoking cessation interventions 2 2 1 1 0 0 6
3. Beliefs about capabilities (n = 15 studies)
Perceptions about patient’s capacity to quit Barrier: patients are already nervous or upset about surgery/diagnosis 1 2 2 1 1 0 7
Barrier: patients lack willpower 1 0 0 0 1 0 2
Perceptions about providers capacity to deliver smoking cessation support Barrier: lack of providers’ self-efficacy to provide treatment 1 0 2 0 1 1 5
Facilitator: Physicians’ belief that their advice is useful 0 0 0 1 0 0 1
4. Social/professional role and identity (n = 9 studies)
Perception of self Barrier: role: providers not believing it is their role to provide smoking cessation treatments 2 0 2 1 0 1 6
Role of institution in addressing tobacco use Barrier: providers not delivering advice about smoking cessation benefits 0 0 0 0 2 0 2
Facilitator: established collaborative smoking cessation program 0 1 0 0 0 0 1
5. Reinforcement (n = 8 studies)
Incentives for quitting smoking Facilitator: surgery itself as a motivator to kickstart quit attempts 0 1 0 3 2 1 7
Facilitator: counselling/advice on surgery-specific benefits of smoking cessation 0 0 0 0 1 0 1
6. Beliefs about consequences (n = 7 studies)
Belief about usefulness of smoking cessation delivery before surgery Barrier: doubts about benefits of short-term abstinence 0 1 1 0 0 0 2
Barrier: smoking cessation interventions not worthwhile given short time before surgery 0 0 1 0 0 0 1
Barrier: underestimation of the effect of smoking cessation on postop complications 1 0 0 0 0 0 1
Barrier: indication for surgery not related to smoking 0 0 1 1 0 0 2
Anticipated regret Barrier: discomfort disclosing smoking status 0 0 0 0 1 0 1
7. Skills (n = 5 studies)
Training and competency to deliver smoking cessation interventions Facilitator: smoking cessation training and awareness of smoking cessation guidelines 1 1 2 0 0 1 5
8. Intentions (n = 4 studies)
Lack of intention Barrier: providers’ belief they cannot influence patients’ decision 1 0 0 0 0 0 1
Perceived readiness to change Barrier: perception that patients don’t want to quit 1 1 0 1 0 0 3
9. Social influences (n = 4 studies)
Normative behaviour Barrier: smoking behaviour of the healthcare provider 2 1 0 0 0 0 3
Smoking among social networks Facilitator: smoking cessation interventions that involve family members who smoke 0 0 0 0 1 0 1
10. Optimism (n = 3 studies)
Pessimism interfering with participation Barrier: Fatalistic given diagnosis requiring surgery 0 0 1 1 1 0 3
11. Emotion (n = 2 studies)
Coping mechanisms for stress Barrier: smoking to cope with psychological stress of illness 0 0 0 0 1 0 1
Lack of meaningful activities Barrier: smoking as only source of enjoyment 0 0 0 0 1 0 1
12. Goals (n = 0 studies)
13. Memory, attention, and decision processes (n = 0 studies)
14. Behavioural regulation (n = 0 studies)

*other: Includes residency program directors.

Fig 2. Frequency of identified themes and sub-themes coded to TDF domains.

Fig 2

Environmental context and resources

The most frequent barriers and facilitators identified in this review were within the environmental context and resources domain, which refers to circumstances or contexts that influence the development of skills. "Time constraints" was the most reported theme across 11 studies, with 12%-48% of anesthesiologists, 7%-49.5% of surgeons, and 50–76% of nurses citing lack of time as a significant barrier to smoking cessation interventions [22,23,43,52]. Patients having surgery often have comorbidities that are prioritized over smoking cessation for example, in one study, a surgeon reports “the discussion of stopping smoking has to be made but invariably the surgeons don’t have time to do it. I have a 45-minute consult and invariably I run over. There’s a lot to talk about in the management of their disease”[23].

The theme “availability of smoking cessation support services" was reported as a barrier to effective smoking cessation by surgeons, anesthesiologists, and residency program directors. Lack of hospital support regarding accessibility and availability of quit kits, Quitline referral materials, nicotine replacement therapy, and lack of integration of care between all professionals and hospital environments involved in the patient’s care were some of the identified barriers within this theme [23]. In one study, vascular surgeons noted it was often unclear what happened to their Quit Line referrals [57]. Clinicians reported medication cost as a barrier, but patients did not mention it in any of the reviewed studies. Clinicians suggested that more patients could be helped if cost was not an issue [57]. In one study of 2,740 surgeons in the United States of America (USA), 40.2% strongly agreed with the statement “reimbursement issues prevent me from providing tobacco-use cessation services” [43].

The theme “person and environment interaction” was reported by clinicians and patients to be a facilitator. The dominant subtheme, mostly reported by patients, was physicians (especially surgeons) proactively providing advice to quit smoking in a sensitive manner and offering help (e.g., NRT) to quit [33,38,40,49,57]. This is exemplified by a quote from a post-surgical patient, “surgeons are probably the most influential people. … [I have a] great respect for their ability and what they did. That is part of selling something like this; we naturally put a lot of stock in the credibility of the person telling us” [59]. In a Canadian study of a “stop smoking before surgery” program, patients were asked to provide feedback to improve the program and most recommended that physicians and surgeons should inform patients about the benefits of quitting smoking [40]. Multiple media sources, including mail, were suggested to disseminate advice to patients due to the limitations of the perioperative environment. Individualization of the timing of smoking cessation advice/interventions was also identified as a facilitator.

Knowledge

Several studies reported the following barriers to smoking cessation delivery in the perioperative setting: inadequate knowledge of the five steps for smoking intervention known as the 5A’s (Ask, Advise, Assess, Assist, and Arrange treatment) and other counseling techniques [19,20,22,23,39], and limited knowledge of NRT efficacy and how to help smokers [20,55]. Providers also believed that perioperative smoking cessation interventions were not efficacious [20,22,33,43,46,49,54]. For example, in a survey of 2,740 oral and maxillofacial surgeons in the USA, only 18% agreed that that counseling to stop smoking was “very or quite effective,” and only 10.6% agreed that counseling patients to remain abstinent was “very or quite effective” [43]. In another study of 83 non-vascular surgeons in the United Kingdom, 45% did not know that counselling patients increased the likelihood of quitting and 48% did not know that augmenting advise with the provision of NRT and referral to cessation services increases the likelihood of successful cessation attempts [46]. Patients had a misconception that smoking was beneficial for their health around the time of surgery, e.g., one patient said, “smoking makes him cough and clears his lungs of mucus” and another reported “quitting smoking will cause me to gain weight and worsen my mobility issues” [38].

Beliefs about capabilities

Perceptions about patient’s capacity to quit was identified as a barrier to abstinence in 15 studies. This included beliefs that patients lack willpower [43], as well as providers reporting that patients are stressed and anxious about surgery hence smoking cessation should not be discussed [22,43,49,52,54,55]. Furthermore, across the studies, the providers’ lack of belief in their self-efficacy to provide smoking cessation treatment was a barrier. For example, only 30% of 443 nurses [49], 39% of 490 anesthesiologists [58] and 20% of 2,740 surgeons [43] believed they had adequate self-efficacy to provide smoking cessation treatments to patients who smoke.

Conversely, physicians are more likely to provide smoking cessation advice to patients when they believe it is useful, which is a facilitator. In a study involving 92 perioperative healthcare providers, those who believed that counseling patients would increase quit rates were significantly more likely to advise patients to quit, with 52.1% of believers taking time to counsel their patients compared to 0.0% of non-believers [19].

Social/Professional role and identity

Providers’ perception that it is not their role to provide smoking cessation interventions was identified as a barrier in six studies. Clinicians sometimes lacked clarity on which professionals had the responsibility to provide support like pharmacotherapy, beyond giving advice. For example, one study [23] reported these quotes from a nurse: ‘I think clinicians have a standard by-line ‘You should quit smoking as it is bad for you’. In terms of committing to other therapies to help them or directing them to what will help them quit, it’s unclear who does that” and from a surgeon “there’s patches and gum and electronic cigarettes and cold turkey or whatever. I’ve got no idea, and I certainly don’t prescribe it. So, I advise them to talk to their GP. Across some of the studies, there was a low proportion of anesthesiologists (42% of 490) [58] and nurses (22% of 443) [49] who felt it was their responsibility to help patients get help. The proportions of surgeons who felt it was their responsibility was slightly higher, 59.4% of 2740 oral and maxillofacial surgeons [43] and 76% of 224 oral surgeons [44] in the two studies involving surgeons that identified this barrier. Conversely in another study, 59.8% of 276 nurses believed it was their responsibility and this was associated with a statistically significant increase in the likelihood of providing smoking cessation counselling [51].

Patients perceive it is the role of clinicians to provide smoking cessation advice and when this is not done, patients identify this as a barrier [38]. In one study, 46% of 150 patients did not receive advise from the clinician and were surprised that this was not discussed [40]. For example, one patient who independently learnt of the benefits of smoking cessation reported that “Yeah, I was kind of surprised as I figured that people would be, you know, really all over the fact that I was a smoker and stuff, but no one really said anything.

From an institutional perspective, the existence of a multi-disciplinary team of surgeons, anesthetists and specialist nurses facilitate the cohesive delivery of the same smoking cessation interventions and avoids mixed messages [23]. A focus group study involving vascular surgeons identified that they believed their responsibility for facilitating smoking cessation treatment should be limited to initiating the conversation with patients and obtaining their agreement to quit. The patients should then be referred to another healthcare provider like a tobacco specialist nurse to ensure that they receive the counselling and treatments. One participant noted “if it’s taken out of the surgeons’ hands, it’s the best thing,” …… “They should be able to say, ‘You need to quit smoking, and here’s a nurse who can help” [57].

Reinforcement

Only facilitators were identified in the domain of reinforcement, from the perspectives of both patients and providers. The theme "incentives for quitting smoking" had two subthemes. Firstly, patients viewed surgery as a major life event, and receiving information about the surgery-specific benefits of quitting smoking served as a motivator to quit [41,57]. In one qualitative study of patients undergoing elective surgery at two hospitals in British Columbia, Canada, most patients agreed that surgery provided new or additional motivation for them to reduce or quit smoking and just learning about the benefits of cessation before surgery prompted an immediate quit attempt [40]. In another survey of 59 patients with peripheral vascular disease having open or endovascular procedures, 77% reported that they reduced smoking because of the surgical intervention itself [32]. Secondly, providers believed the preoperative period is an opportune time to use impending surgery as an incentive for patients to quit smoking permanently [20,22,58].

Belief about consequences

Only barriers were identified within this domain, across 7 studies. The main theme was “belief about usefulness of smoking cessation delivery before surgery”. Some providers expressed doubts about the benefits of short-term abstinence around the time of surgery, and the efforts to initiate smoking cessation were not worthwhile given the short time patients are seen before surgery [51,54]. Also providers underestimate the effect of smoking cessation on postoperative complications [46]. Sometimes, smoking cessation was not discussed as providers felt the indication for surgery was not related to smoking and that the health issue requiring surgery took precedence [19,50].

The theme "anticipated regret" within this domain shows that patients may feel regret about their smoking and disclosing this to their healthcare provider. This feeling of discomfort could be a barrier, stemming from a sense of self-failure. In a qualitative study of 22 lung cancer patients, a patient reported “I felt ashamed. I’ve done this to myself you know. It’s my fault I’ve got it…I don’t think anyone realizes how addictive it is, and I feel it should be banned, cause it’s a drug, you know… I couldn’t give it up so. But I did in the end, but too late”. It could also stem from feelings of guilt or fear of disappointing their health care provider for example, another patient in the study reported “It’s hard because [my GP has] been very good with me. You feel like you’re wasting their time, you feel guilty, but she was great with me and she…asked me what I wanted to help me stop” [38].

Skills

Across 5 studies, surgeons, anesthesiologists, and nurses identified that training on smoking cessation [43,51,54,58] and awareness of smoking cessation guidelines [22,43,51,58] were important facilitators. In two studies, this was associated with increased provision of smoking cessation counselling, fewer perceived barriers, and an increase in self-efficacy to deliver smoking cessation interventions among nurses and surgeons [43,51].

Intentions

Providers’ beliefs about their inability to influence patients and their perceived patients’ lack of readiness to quit, were barriers in this domain. In one study of 200 thoracic surgeons, 160 (80%) believed that patient’s unwillingness to quit smoking was the main barrier interfering with their ability to help them quit smoking [45]. Another study showed that only 27% of 823 surgeons always advised patients to quit smoking. Surgeons who didn’t advise patients to quit smoking, gave not being able to influence them as the main reason (39.4%) [48].

Social influences

The theme "normative behavior" refers to how the smoking norms, attitudes, and behaviors of healthcare providers impact their willingness to provide smoking cessation care. Providers who use tobacco are less likely to believe in the harms of smoking and less likely to provide cessation interventions [22,43,48]. In a survey of 542 anesthesiologists and 521 surgeons, physicians who smoked were less likely to agree that the perioperative period was a good time to help patients stop smoking (15% of smokers vs 36% and of non-smokers, P<0.0001), less likely to agree it was their responsibility to advise patients to quit (15% versus 27%, P = 0.01), and less likely to oppose strict hospital smoking policies (23% vs 52%, P<0.0001) [22].

The involvement of a patient’s social network to provide social support was a facilitator from patients’ perspective. In a study involving 8 patients and their family members who smoked in a thoracic surgery clinic, a patient reported, “I was confident I could stop smoking this time, knowing that we were both going to quit together. We very seldom do anything without each other. His spouse stated, “At first, I was very skeptical. I thought I couldn’t do it. But overcoming this together gave us the needed support. I’m confident now that we will stay smoke-free” [41].

Emotion

The two themes in this domain came from one study involving surgical lung cancer patients and were barriers to smoking cessation intervention in the perioperative period [38]. Patients identified that smoking was used as a mechanism to relieve the stress of their illness/diagnosis and a way to retain some enjoyment in their lives. For example, one participant in the study reported, “I’m 66…I don’t expect to live much longer. And when you see this world, I don’t know whether I want to. I’m alright. … I just want to be happy and if a cigarette makes me happy, why shouldn’t I have one. …I know I’m naughty and I shouldn’t do it… but I’m ok”.

Discussion

What is new: our study is the first theory-informed scoping review examining barriers and facilitators to smoking cessation in the perioperative setting. Key finding include: i.) more barriers (23) than facilitators (13) to perioperative smoking cessation were identified; ii.) primary barriers encompass lack of time (number of studies n = 13), limited knowledge among providers (n = 10), and belief about patient apprehension about pre-surgery cessation discussions (n = 7); iii.) significant facilitators are using surgery as a motivation to quit (n = 7) and physician-provided cessation advice(n = 5). Notably, the link between these factors and cessation success remains unexplored. Our findings indicate a need for a comprehensive approach to implement effective perioperative smoking cessation strategies, addressing multiple identified barriers across several domains.

Lack of time and availability of smoking cessation support services were important barriers. System-level changes such as the establishment of smoking cessation programs and increasing clinic time for providers are needed, along with reimbursement for counselling patients or innovative solutions like the use of computer-based programs [60] or virtual care models [61] to deliver smoking cessation to patients. Except for one study [47], all were conducted in high and upper-middle-income countries. Since reimbursement systems differ across healthcare settings, any system-level changes must be tailored to the specific context.

Clinic workflow and the time of surgeons and anesthesiologists who are trained to perform surgery and maintain patients optimally around the time of surgery can be optimized if the brief advice provided by the surgeon/anesthetist is followed by prompt referral to a smoking cessation expert, tobacco Quitline or smoking clinic integrated into the perioperative service. In a busy perioperative service in a Canadian hospital, this type of care integration increased the rate of identifying smokers; pre-implementation only 8.6% of patients were asked about smoking whereas, post-implementation, this rose to 86.0%. Consequently, the rate of providing an initial treatment intervention to smokers increased from 0% to 67.5% but there was no data on whether this improved smoking cessation rates [62].

There is a crucial need to establish smoking cessation training programs across the spectrum of perioperative care providers, including within residency curricula [58]. Increasing clinicians’ knowledge leads to increases in smoking cessation delivery to patients [63]. A Cochrane review of 17 RCTs from mostly high-income countries demonstrated that training health professionals to provide smoking cessation interventions increased professional performance on asking, counselling, and assisting smokers in their quit attempt, and increased continuous abstinence from smoking (OR 1.60, 95% CI 1.26 to 2.03, p = 0.03) [64]. In the perioperative setting, technology can be leveraged to increase clinician engagement, by delivering training in formats (e.g., online) that will allow clinicians to earn CME credit and include pathways to reimbursement for example, the American College of Surgeons Division of Education Surgical Smoking Cessation in the Surgical Patient program 1-hour online course.

Misconceptions that patients are too nervous about surgery to discuss smoking cessation needs to be addressed through education. There is evidence that patients who smoke want to quit [7], and we found in this review that surgery itself is a facilitator for smoking cessation [65,66]. Smoking cessation before surgery reduces postoperative complications [6769] and practice guidelines recommend smoking cessation at least 4 weeks before surgery [13]. In clinical practice, patients are often seen just before surgery, and this may inform the belief that smoking cessation interventions are not worthwhile given the short time frame in which patients are seen. However, there is evidence that smoking cessation even a few days before surgery reduces the risk of post-surgical complications [70]. Moreover, beyond reducing complications, helping patients quit smoking for surgery has the potential for long-term abstinence [71] and therefore long-term health benefits.

We found common barriers to smoking cessation related to emotions, such as smoking for enjoyment or stress relief, particularly in cancer patients, and social influences, including healthcare providers’ smoking behaviors. This suggests the necessity for tailored smoking cessation strategies in this group, emphasizing the improved prognosis for those who quit even after a cancer diagnosis [72]. Family involvement may be beneficial, and the influence of healthcare providers’ attitudes on their smoking habits needs further study. A recent systematic review and meta-analysis of 246 studies and 497,081 physicians, found that although there was a downward trend in smoking prevalence among physicians, it was still high at 21% (95% CI 20% - 23%) [73]. None of our identified studies evaluated the impact of tobacco cessation among healthcare providers on smoking outcomes for patients. Hospital smoking cessation programs need to account for health care provider smoking behavior.

Limitations

Limitations of this review include firstly, we only including articles published in English which were heterogenous and of varied sample sizes, potentially limiting its generalizability to other non-English speaking settings and with different sociocultural and environmental contexts. Secondly, we were unable to quantify whether the identified barriers and facilitators were considered trivial, moderate, or large as this was not assessed in the individual studies. Thirdly, our theme choices were guided by the TDF rather than by strictly inductive analysis. This might have led us to miss unique or unexpected themes that didn’t fit the established TDF domains. Lastly, the subjective nature of our quality assessment with the MMAT scoring, might have introduced some author bias.

Conclusions

Key domains that influence perioperative smoking cessation are environmental context and resources, knowledge, beliefs about capabilities, professional roles and identities and reinforcement. Specific barriers from providers include lack of time, lack of knowledge of smoking cessation interventions and smoking cessations support. Specific barriers from patients include failure of providers to advise them to quit whereas surgery itself serves as a motivator to quit smoking. High-quality evidence is needed to determine whether modifying these factors will impact patient smoking outcomes.

Supporting information

S1 Fig. Number of barriers and facilitators mapped to each TDF domain.

(DOCX)

pone.0298233.s001.docx (29.8KB, docx)
S1 Table. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist.

(DOCX)

pone.0298233.s002.docx (26.4KB, docx)
S2 Table. Search strategies.

(DOCX)

pone.0298233.s003.docx (26.7KB, docx)
S3 Table. Quality assessment of included studies with the Mixed Methods Appraisal Tool (MMAT).

(DOCX)

pone.0298233.s004.docx (19.8KB, docx)
S1 File. Reports excluded at full text screening stage.

(DOCX)

pone.0298233.s005.docx (24.8KB, docx)

Data Availability

All data files are available from the Open science Framework (OSF) database: https://osf.io/z3pyd/?view_only=c621853d3da0494082da159907058be6.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.GBD 2015 Tobacco Collaborators MB, Fullman N, Ng M, Salama JS, Abajobir A, Abate KH, et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet. 2017;389(10082):1885–906. doi: 10.1016/S0140-6736(17)30819-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Warner DO. Surgery as a teachable moment: Lost opportunities to improve public health. Archives of Surgery. 2009;144(12):1106–7. doi: 10.1001/archsurg.2009.205 [DOI] [PubMed] [Google Scholar]
  • 3.Shi Y, Warner DO. Surgery as a teachable moment for smoking cessation. Anesthesiology. 2010;112(1):102–7. doi: 10.1097/ALN.0b013e3181c61cf9 [DOI] [PubMed] [Google Scholar]
  • 4.Turan A, Mascha EJ, Roberman D, Turner PL, You J, Kurz A, et al. Smoking and perioperative outcomes. Anesthesiology. 2011;114(4):837–46. doi: 10.1097/ALN.0b013e318210f560 [DOI] [PubMed] [Google Scholar]
  • 5.Howard R, Singh K, Englesbe M. Prevalence and Trends in Smoking Among Surgical Patients in Michigan, 2012–2019. JAMA Network Open. 2021. Mar 3;4(3):e210553–e210553. doi: 10.1001/jamanetworkopen.2021.0553 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Heiden BT, Smock N, Pham G, Chen J, Craig EJ, Meyers BF, et al. Underutilization of Guideline-Concordant Smoking Cessation Treatments in Surgical Patients: Lessons from a Learning Health System. Annals of Surgery Open 2022;3(1). doi: 10.1097/as9.0000000000000144 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Centers for Disease Control and Prevention. Current Cigarette Smoking Among Adults in the United States 2020. Available from: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smoking/index.htm#nation
  • 8.Gajdos C, Hawn MT, Campagna EJ, Henderson WG, Singh JA, Houston T. Adverse Effects of Smoking on Postoperative Outcomes in Cancer Patients. Ann Surg Oncol 2012;19(5):1430–8. doi: 10.1245/s10434-011-2128-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Sørensen LT. Wound Healing and Infection in Surgery. Ann Surg. 2012;255(6):1069–79. [DOI] [PubMed] [Google Scholar]
  • 10.Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;(5):CD009329. doi: 10.1002/14651858.CD009329.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Rigotti NA, Clair C, Munafò MR, Stead LF. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2012;5(5):CD001837–CD001837. doi: 10.1002/14651858.CD001837.pub3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database of Systematic Reviews. 2016; 3:CD008286. doi: 10.1002/14651858.CD008286.pub3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Pierre S, Rivera C, Le Maitre B, Ruppert AM, Chaput B, Bouaziz H, et al. Guidelines on preoperative smoking cessation. Anesthesie et Reanimation. 2016;2(5):368–76. [Google Scholar]
  • 14.Pierre S, Rivera C, le Maitre B, Ruppert AM, Bouaziz H, Wirth N, et al. Guidelines on smoking management during the perioperative period. Anaesth Crit Care Pain Med. 2017;36(3):195–200. doi: 10.1016/j.accpm.2017.02.002 [DOI] [PubMed] [Google Scholar]
  • 15.Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, et al. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery. Can J Cardiol. 2017;33(1):17–32. doi: 10.1016/j.cjca.2016.09.008 [DOI] [PubMed] [Google Scholar]
  • 16.Ofori SN, Marcucci M, Mbuagbaw L, Conen D, Borges FK, Chow CK, et al. Determinants of tobacco smoking abstinence 1 year after major noncardiac surgery: a secondary analysis of the VISION study. Br J Anaesth. 2022; 129(4):497–505. [DOI] [PubMed] [Google Scholar]
  • 17.Ravi K, Indrapriyadharshini K, Madankumar PD. Application of Health Behavioral Models in Smoking Cessation ‐ A Systematic Review. Indian J Public Health. 2021;65(2):103–9. doi: 10.4103/ijph.IJPH_1351_20 [DOI] [PubMed] [Google Scholar]
  • 18.Minian N, Corrin T, Lingam M, deRuiter WK, Rodak T, Taylor VH, et al. Identifying contexts and mechanisms in multiple behavior change interventions affecting smoking cessation success: a rapid realist review. BMC Public Health. 2020. Jun;20(1):918. doi: 10.1186/s12889-020-08973-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Vick CC, Graham LA, Henderson WG, Houston TK II, Hawn MT. Translating preoperative smoking cessation interventions into routine clinical care of veterans: Provider beliefs. Transl Behav Med. 2011;1(4):604–8. doi: 10.1007/s13142-011-0096-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Warner DO, Sarr MG, Offord KP, Dale LC. Anesthesiologists, general surgeons, and tobacco interventions in the perioperative period. Anesth Analg. 2004;99(6):1766–73. doi: 10.1213/01.ANE.0000136773.40216.87 [DOI] [PubMed] [Google Scholar]
  • 21.Yousefzadeh A, Chung F, Wong DT, Warner DO, Wong J. Smoking Cessation: The Role of the Anesthesiologist. Anesth Analg. 2016;122(5):1311–20. doi: 10.1213/ANE.0000000000001170 [DOI] [PubMed] [Google Scholar]
  • 22.Kai T, Maki T, Takahashi S, Warner DO. Perioperative tobacco use interventions in Japan: a survey of thoracic surgeons and anaesthesiologists. Br J Anaesth. 2008;100(3):404–10. doi: 10.1093/bja/aem400 [DOI] [PubMed] [Google Scholar]
  • 23.Luxton NA, MacKenzie R, Shih P. Smoking Cessation Care in Cardiothoracic Surgery: A Qualitative Study Exploring the Views of Australian Clinicians. Heart Lung Circ. 2019;28(8):1246–52. doi: 10.1016/j.hlc.2018.04.293 [DOI] [PubMed] [Google Scholar]
  • 24.Cane J, O’Connor D, Michie S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implementation Science. 2012;7(1):37. doi: 10.1186/1748-5908-7-37 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Cowdell F, Dyson J. How is the theoretical domains framework applied to developing health behaviour interventions? A systematic search and narrative synthesis. BMC Public Health. 2019;19(1):1180. doi: 10.1186/s12889-019-7442-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Campbell KA, Fergie L, Coleman-Haynes T, Cooper S, Lorencatto F, Ussher M, et al. Improving Behavioral Support for Smoking Cessation in Pregnancy: What Are the Barriers to Stopping and Which Behavior Change Techniques Can Influence These? Application of Theoretical Domains Framework. Int J Environ Res Public Health. 2018. Feb;15(2). doi: 10.3390/ijerph15020359 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Huddlestone L, Shoesmith E, Pervin J, Lorencatto F, Watson J, Ratschen E. A Systematic Review of Mental Health Professionals, Patients, and Carers’ Perceived Barriers and Enablers to Supporting Smoking Cessation in Mental Health Settings. Nicotine and Tobacco Research. 2022;24(7):945–54. doi: 10.1093/ntr/ntac004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Aromataris E MZ, editor. JBI Manual for Evidence Synthesis. 2020.
  • 29.Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med 2018. Sep 4;169(7):467–73. doi: 10.7326/M18-0850 [DOI] [PubMed] [Google Scholar]
  • 30.Hong QN, Pluye P, Fábregues S, Bartlett G, Boardman F, Cargo M, et al. Mixed Methods Appraisal Tool (MMAT), version 2018. Registration of Copyright (#1148552), Canadian Intellectual Property Office, Industry Canada. 2018. [Google Scholar]
  • 31.Newhall K, Suckow B, Spangler E, Brooke BS, Schanzer A, Tan TW, et al. Impact and duration of brief surgeon-delivered smoking cessation advice on attitudes regarding nicotine dependence and tobacco harms for patients with peripheral arterial disease. Ann Vasc Surg. 2017;38:113–21. doi: 10.1016/j.avsg.2016.06.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Rajaee S, Holder T, Indes JE, Muhs B, Sarac T, Sumpio B, et al. A Pilot Study of a Standardized Smoking Cessation Intervention for Patients with Vascular Disease. Ann Vasc Surg 2019; 61:91–9. doi: 10.1016/j.avsg.2019.06.017 [DOI] [PubMed] [Google Scholar]
  • 33.Shannon-Cain J, Webster SF, Cain BS. Prevalence of and reasons for preoperative tobacco use. AANA J. 2002;70(1):33–40. [PubMed] [Google Scholar]
  • 34.Smeds MR, Privratsky A, Thrush CR, Barone CP, Escobar GA, Ali AT, et al. Nicotine Dependence and Willingness to Quit Smoking in Vascular Surgery Patients. Ann Vasc Surg. 2017;45:144–53. doi: 10.1016/j.avsg.2017.06.049 [DOI] [PubMed] [Google Scholar]
  • 35.Van Slyke AC, Carr M, Knox ADC, Genoway K, Carr NJ. Perioperative and long-term smoking behaviors in cosmetic surgery patients. Plast Reconstr Surg. 2017;140(3):503–9. doi: 10.1097/PRS.0000000000003604 [DOI] [PubMed] [Google Scholar]
  • 36.Webb AR, Robertson N, Sparrow M. Smokers know little of their increased surgical risks and may quit on surgical advice. ANZ J Surg. 2013;83(10):753–7. doi: 10.1111/ans.12096 [DOI] [PubMed] [Google Scholar]
  • 37.Yu C, Luo A, Kadimpati S, Shi Y, Warner DO, Sheng Y, et al. Perioperative smoking behavior of chinese surgical patients. Anesth Analg. 2013;116(6):1238–46. doi: 10.1213/ANE.0b013e31828e5cf0 [DOI] [PubMed] [Google Scholar]
  • 38.Farley A, Dowswell G, Aveyard P, Kerr A, Naidu B. Surgical lung cancer patients’ views about smoking and support to quit after diagnosis: a qualitative study. J Cancer Surviv. 2016;10(2):312–9. doi: 10.1007/s11764-015-0477-4 [DOI] [PubMed] [Google Scholar]
  • 39.Warner DO, Klesges RC, Dale LC, Offord KP, Schroeder DR, Vickers KS, et al. Telephone quitlines to help surgical patients quit smoking patient and provider attitudes. Am J Prev Med. 2008;35(6 Suppl):S486-93. doi: 10.1016/j.amepre.2008.08.032 [DOI] [PubMed] [Google Scholar]
  • 40.Bottorff JL, Seaton CL, Viney N, Stolp S, Krueckl S, Holm N. The Stop Smoking Before Surgery Program: Impact on Awareness of Smoking-Related Perioperative Complications and Smoking Behavior in Northern Canadian Communities. J Prim Care Community Health 2016;7(1):16–23. doi: 10.1177/2150131915604827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.McDonnell KK, Bullock LF, Kozower BD, Hollen PJ, Heath J, Rovnyak V. A decision aid to improve smoking abstinence for families facing cancer. Oncol Nurs Forum. 2014;41(6):649–58. doi: 10.1188/14.ONF.649-658 [DOI] [PubMed] [Google Scholar]
  • 42.McDonnell KK, Hollen PJ, Heath J, Andrews JO. Recruiting family dyads facing thoracic cancer surgery: Challenges and lessons learned from a smoking cessation intervention. European Journal of Oncology Nursing. 2016;20:199–206. doi: 10.1016/j.ejon.2015.08.006 [DOI] [PubMed] [Google Scholar]
  • 43.Crews KM, Shefffer CE, Payne TJ, Applegate BW, Martin A, Sutton T. A survey of oral and maxillofacial surgeons’ tobacco-use-related knowledge, attitudes and intervention behaviors. Journal of the American Dental Association. 2008;139(12):1643–51. doi: 10.14219/jada.archive.2008.0106 [DOI] [PubMed] [Google Scholar]
  • 44.Gay-Escoda C, González-Martínez R, Delgado-Molina E. A survey of oral surgeons’ tobacco-use-related knowledge and intervention behaviors. Med Oral Patol Oral Cir Bucal. 2012;17(4):10–5. doi: 10.4317/medoral.17724 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Marrufo AS, Kozower BD, Tancredi DJ, Nuno M, Cooke DT, Pollock BH, et al. Thoracic Surgeons’ Beliefs and Practices on Smoking Cessation Before Lung Resection. Ann Thorac Surg. 2019;107(5):1494–9. doi: 10.1016/j.athoracsur.2018.11.055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Owen D, Lind J, Harrison R, Hilton C, Jalloh I, Owen M, et al. Preoperative smoking cessation: A questionnaire study. Int J Clin Pract 2007;61(12):2002–2004. doi: 10.1111/j.1742-1241.2007.01565..x [DOI] [PubMed] [Google Scholar]
  • 47.Saddichha S, Rekha DP, Patil BK, Murthy P, Benegal V, Isaac MK. Knowledge, attitude and practices of indian dental surgeons towards tobacco control: Advances towards prevention. Asian Pacific Journal of Cancer Prevention. 2010;11(4):939–42. [PubMed] [Google Scholar]
  • 48.Yao T, Ong M, Lee A, Jiang Y, Mao Z. Smoking knowledge, attitudes, behavior, and associated factors among Chinese male surgeons. World J Surg. 2009;33(5):910–7. doi: 10.1007/s00268-009-9938-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Houghton CS, Marcukaitis AW, Shirk Marienau ME, Hooten M, Stevens SR, Warner DO. Tobacco intervention attitudes and practices among certified registered nurse anesthetists. Nurs Res. 2008;57(2):123–9. doi: 10.1097/01.NNR.0000313481.39755.ea [DOI] [PubMed] [Google Scholar]
  • 50.Taniguchi C, Hibino F, Kawaguchi E, Maruguchi M, Tokunaga N, Saka H, et al. Perceptions and practices of Japanese nurses regarding tobacco intervention for cancer patients. J Epidemiol. 2011;21(5):391–7. doi: 10.2188/jea.JE20110008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Yankie VM, Price HM, Nanfito ER, Jasinski DM, Crowell NA, Heath J. Providing smoking cessation counseling: A national survey among nurse anesthetists. Crit Care Nurs Clin North Am. 2006;18(1):123–9. doi: 10.1016/j.ccell.2005.10.007 [DOI] [PubMed] [Google Scholar]
  • 52.Jose T, Barrone ML, Johnson WS, Larsen HA, Martin EE, Marienau MS, et al. Feasibility of Nurse-Managed Tobacco Use Interventions in Outpatient Surgical Practice. J Perianesth Nurs. 2020;35(3):307–13. doi: 10.1016/j.jopan.2019.10.009 [DOI] [PubMed] [Google Scholar]
  • 53.Rosvall A, Carlson E. Registered nurses’ perception of self-efficacy and competence in smoking cessation after participating in a web-based learning activity. J Clin Nurs. 2017;26(23–24):4777–85. doi: 10.1111/jocn.13831 [DOI] [PubMed] [Google Scholar]
  • 54.Shi Y, Yu C, Luo A, Huang Y, Warner DO. Perioperative tobacco interventions by chinese anesthesiologists: Practices and attitudes. Anesthesiology. 2010;112(2):338–46. doi: 10.1097/ALN.0b013e3181c91ee7 [DOI] [PubMed] [Google Scholar]
  • 55.Karabeyoglu I, Gokcinar D, Karabeyoglu M, Baydar M, Gogus N. Anesthesiologists’, general surgeons’ and residents’ perceptions of the perioperative smoking cessation of patients. Acta Medica Mediterranea. 2014;30(6):1233–8. [Google Scholar]
  • 56.Warner DO, Sarr MG, Offord KP, Dale LC. Anesthesiologists, general surgeons, and tobacco interventions in the perioperative period. Anesth Analg. 2004. Dec;99(6):1766–73. doi: 10.1213/01.ANE.0000136773.40216.87 [DOI] [PubMed] [Google Scholar]
  • 57.Newhall K, Burnette M, Brooke BS, Schanzer A, Tan T, Flocke S, et al. Smoking cessation counseling in vascular surgical practice using the results of interviews and focus groups in the Vascular Surgeon offer and report smoking cessation pilot trial. J Vasc Surg. 2016. Apr;63(4):1011–7.e2 doi: 10.1016/j.jvs.2015.10.086 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Schultz CR, Benson JJ, Cook DA, Warner DO. Training for perioperative smoking cessation interventions: A national survey of anesthesiology program directors and residents. J Clin Anesth. 2014;26(7):563–9. doi: 10.1016/j.jclinane.2014.04.008 [DOI] [PubMed] [Google Scholar]
  • 59.Warner DO, Klesges RC, Dale LC, Offord KP, Schroeder DR, Vickers KS, et al. Telephone Quitlines to Help Surgical Patients Quit Smoking. Patient and Provider Attitudes. Am J Prev Med. 2008;35(6SUPPL):S486–93. [DOI] [PubMed] [Google Scholar]
  • 60.Wolfenden L, Wiggers J, Campbell E, Knight J, Kerridge R, Spigelman A. Providing comprehensive smoking cessation care to surgical patients: the case for computers. Drug Alcohol Rev. 2009;28(1):60–5. doi: 10.1111/j.1465-3362.2008.00003.x [DOI] [PubMed] [Google Scholar]
  • 61.McGillion MH, Parlow J, Borges FK, Marcucci M, Jacka M, Adili A, et al. Post-discharge after surgery Virtual Care with Remote Automated Monitoring-1 (PVC-RAM-1) technology versus standard care: randomised controlled trial. BMJ 2021;374:n2209. doi: 10.1136/bmj.n2209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Sadek J, Moloo H, Belanger P, Nadeau K, Aitken D, Foss K, et al. Implementation of a systematic tobacco treatment protocol in a surgical outpatient setting: a feasibility study. Can J Surg. 2021;64(1):E51–8. doi: 10.1503/cjs.009919 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Herie M, Connolly H, Voci S, Dragonetti R, Selby P. Changing practitioner behavior and building capacity in tobacco cessation treatment: The TEACH project. Patient Educ Couns. 2012;86(1):49–56. doi: 10.1016/j.pec.2011.04.018 [DOI] [PubMed] [Google Scholar]
  • 64.Carson K V, Verbiest MEA, Crone MR, Brinn MP, Esterman AJ, Assendelft WJJ, et al. Training health professionals in smoking cessation. Cochrane Database Syst Rev. 2012;(5):CD000214. doi: 10.1002/14651858.CD000214.pub2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.He Y, Tan M, Sim XLJ, Abdullah HR, Shi M, Lum E, et al. Smoking characteristics and readiness-to-quit status among smokers attending preoperative assessment clinic ‐ a prospective cohort study. Risk Manag Healthc Policy. 2021;14:2483–90. doi: 10.2147/RMHP.S312950 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Baker A, Dean EP, Ishikawa SN, Murphy GA, Grear BJ, Richardson DR. Patient perceptions and willingness to stop smoking prior to foot and ankle surgery. Curr Orthop Pract. 2018;29(6):556–9. [Google Scholar]
  • 67.Mills E, Eyawo O, Lockhart I, Kelly S, Wu P, Ebbert JO. Smoking Cessation Reduces Postoperative Complications: A Systematic Review and Meta-analysis. Am J Med. 2011;124(2):144–154.e8. doi: 10.1016/j.amjmed.2010.09.013 [DOI] [PubMed] [Google Scholar]
  • 68.Moore S, Mills BB, Moore RD, Miklos JR, Mattox TF. Perisurgical smoking cessation and reduction of postoperative complications. Am J Obstet Gynecol. 2005;192(5):1718–21. doi: 10.1016/j.ajog.2004.11.048 [DOI] [PubMed] [Google Scholar]
  • 69.Jung KH, Kim SM, Choi MG, Lee JH, Noh JH, Sohn TS, et al. Preoperative smoking cessation can reduce postoperative complications in gastric cancer surgery. Gastric Cancer 2015;18(4):683–90. doi: 10.1007/s10120-014-0415-6 [DOI] [PubMed] [Google Scholar]
  • 70.Wong J, Lam DP, Abrishami A, Chan MT V, Chung F. Short-term preoperative smoking cessation and postoperative complications: a systematic review and meta-analysis. Can J Anaesth. 2012;59(3):268–79. doi: 10.1007/s12630-011-9652-x [DOI] [PubMed] [Google Scholar]
  • 71.Wong J, Abrishami A, Riazi S, Siddiqui N, You-Ten E, Korman J, et al. A Perioperative Smoking Cessation Intervention with Varenicline, Counseling, and Fax Referral to a Telephone Quitline Versus a Brief Intervention: A Randomized Controlled Trial. Anesth Analg. 2017;125(2):571–9. doi: 10.1213/ANE.0000000000001894 [DOI] [PubMed] [Google Scholar]
  • 72.Sheikh M, Mukeriya A, Shangina O, Brennan P, Zaridze D. Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality: A Prospective Cohort Study. Ann Intern Med. 2021;174(9):1232–9. doi: 10.7326/M21-0252 [DOI] [PubMed] [Google Scholar]
  • 73.Besson A, Tarpin A, Flaudias V, Brousse G, Laporte C, Benson A, et al. Smoking Prevalence among Physicians: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2021;18(24):13328. doi: 10.3390/ijerph182413328 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Silvia Fiorelli

14 Jun 2023

PONE-D-23-16365Barriers and facilitators to preoperative smoking cessation: a scoping reviewPLOS ONE

Dear Dr. OFORI,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

please assess all the reviewers comments 

==============================

Please submit your revised manuscript by Jul 29 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Silvia Fiorelli

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. 

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

4. Please amend either the title on the online submission form (via Edit Submission) or the title in the manuscript so that they are identical.

5. We note that this manuscript is a systematic review or meta-analysis; our author guidelines therefore require that you use PRISMA guidance to help improve reporting quality of this type of study. Please upload copies of the completed PRISMA checklist as Supporting Information with a file name “PRISMA checklist”.

6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: N/A

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

********** 

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: State source of funding

The Short title applies to a wider scope

Please clarify what informed the choice of the search engines

Background- the figure 2.4% , not clear if it applies to the whole population or only to smokers

Provide key or footnote in your diagrams and tables

Reviewer #2: Thanks for submitting this manuscript.

I have multiple points to the authors to consider or to clarify on the manuscript:

1- Please state the qualifications of the reviewers including the third one. Line 122 and 126.

2- Could you state whether the selected studies were theory-base or not. Table 1.

3- Please review line 260 for miss spelling reported.

4- Please review line 382 for clarify.

5- I suggest to split table 2 to two tables. One for health care providers and one for patients only for easy reading.

Best wishes,

********** 

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Jun 11;19(6):e0298233. doi: 10.1371/journal.pone.0298233.r002

Author response to Decision Letter 0


29 Jun 2023

We have responded to all reviewers and editor comments in the "Response to Reviewers" document attached to this submission. Thank you.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0298233.s006.docx (22.8KB, docx)

Decision Letter 1

Silvia Fiorelli

4 Sep 2023

PONE-D-23-16365R1Barriers and facilitators to perioperative smoking cessation: a scoping reviewPLOS ONE

Dear Dr. OFORI,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

please carefully assess all the reviewers comments

===========

Please submit your revised manuscript by Oct 19 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Silvia Fiorelli

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

Reviewer #3: Introduction, line 68 – I think you mean systems-led behavior change or system-level support to lead to behavior change?

Suggested copy edit:

The theoretical domains framework (TDF) is an evidence-based, comprehensive framework that can help understand the determinants of behavior change [24].

Section 2.1, add appendix reference next to mesh terms so people know where they can find it.

Section 2.2 should be cleaned up; you are referring to eligibility of all the studies but it is a bit confusing with the participants and semi-colon. Maybe start broad e.g., criteria as it related to all studies and then specify that studies could include your specified population. You also seem to be missing more specification for your exclusion criteria, a lot of the articles you exclude on in the PRISMA are not specified criteria in this section.

These sentences are found in the section above eligibility criteria, but are not in the appropriate section:

The search was restricted to 109 English language articles published in 2000 or later.

AND

We screened systematic reviews 111 for individual studies that met the eligibility criteria.

Could the authors include a citation for the approach to quality reporting (section 2.5) starting on line 138-9? Is this standard practice, some justification for this approach is necessary.

I find this sentence really confusing in the data synthesis section: From quantitative studies, we summarized the proportion of participants who report negative or permissive attitudes towards smoking and provide smoking cessation support/interventions as numbers and percentages. I don’t think a reader could replicate this, could you be clearer in how someone would reproduce this approach.

You use HCP on page 7 line 173 for the first time and don’t define it.

Results, the authors don’t really address that family members are included in some of these studies as are there perspectives, should this not be added in some way beyond Table 1, or if the authors choose not to report it, state that and why? It looks like it is only brought up once in the results.

It seems like the authors report on “other” in Table 2, is the family members? Could you better define this in the table – what is this subgroup comprised of?

Could the authors explain how they differentiate between capabilities vs. motivation? Are these articles actually talking about self-efficacy overall or is motivation salient here, if so, should the table be updated?

Aren’t these two items in table 2, category 6, not knowledge issues? Misperceptions?

- Barrier: indication for surgery not related to smoking

- Barrier: underestimation of the effect of smoking cessation on postop complications

Table 2, category 8, is lack of intentions the right word here? The way it os described in the table doesn’t seem like it’s a lack of intention on the part of the providers but a lack of belief in the outcome from the providers perspective, also by stage of change do you mean perceived readiness to change?

Also, a general comment is you do have a category that is decision processes, it seems to me that anything related to stages of change or motivation to change should go here - Suggest revising.

Could you walk me through why pessimism fits in the optimism them? It seems like the opposite.

The authors need to specifically cite the studies that this relates to in the following sentence on Page 15 - Lack of hospital support regarding accessibility and availability of quit kits [cite], Quitline referral materials [cite], nicotine replacement therapy [cite], and lack of integration of care between all professionals [cite] and hospital environments [cite] involved in the patient's care were some of the identified barriers within this theme [23].

Page 15, suggest you add what country this is in as there is a lot of variation in this study: In one study of 2,740 surgeons, 215 40.2% strongly agreed with the statement “reimbursement issues prevent me from providing 216 tobacco-use cessation services”?

Under the knowledge heading on page 16, the citations should not all be piled at the end but linked to the specific points in the sentence, please revise.

Under the knowledge heading, was this pattern globally providers had a misconception? Was it restricted to certain regions? This would be important specification to add.

Skills section, first sentence could you move the citations to the training or awareness section so the reader can know what article links to what statement?

Intentions heading, you have readiness to change in the table, but you don’t comment on it in this section.

For the key findings could you also numerically add the number of studies that outline these findings for each point? e.g. barriers (n) vs facilitators (n)

Line 372- discussion is an important point, however, given the breadth of studies this review covers, it is a little too broad of a comment. The authors should consider how this comment relates to different health care systems which articles in this review cover, I would imagine some countries do have very different reimbursements or even some specialities might have more integration than others? I would suggest the authors spend some time looking at the differences and revise this section accordingly, so it isn’t just western based recommendations or at least accounts for different healthcare systems.

Same reflection to line 391 – discussion, is the Cochrane review restricted to certain regions or healthcare systems? Specify

The first part of this sentence needs a citation: There is compelling evidence that patients who smoke want to quit, [cite] and we found in this review that surgery itself is a facilitator for smoking cessation [65,66].

Is this assertion true for this part of the sentence on line 411, discussion? - helping patients quit smoking for surgery has the potential for long-term abstinence? – could you cite

Limitations – given that you used a theoretical framework you tried to fit your themes into this framework rather than generate them inductively, you may want to mention this, I also think the authors needs to comment on generalizability as some of the articles were very small samples vs others and that there was large heterogeneity across the articles. Also missing authors bias, there seems to be a high level of subjectivity about the quality of the articles and the MMAT assessment, it seems like this should be acknowledged.

Figure 1 prisma, you have *’s that don’t link with anything, could you add footnotes for these symbols and make sure you include why records were excluded in the first part of the diagram too, not just the last.

Comment on supplemental materials – the formatting looks a bit messy for the search criteria - extra letters ect. like it was just thrown together, could you clean these up or make the tables consistent in some way?

Table 1 looks ok to me.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #3: Yes: Teresa DeAtley

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Decision Letter 2

Silvia Fiorelli

7 Nov 2023

PONE-D-23-16365R2Barriers and facilitators to perioperative smoking cessation: a scoping reviewPLOS ONE

Dear Dr. ONOFRI,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: Pplease carefully assess all the reviewers comments 

Please submit your revised manuscript by 7 December 2023. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Silvia Fiorelli

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #4: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: I Don't Know

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

Reviewer #4: 1. In general, the background has a bit too much detail on prior work (particularly lines 80-88) - would keep intro more succinct and add this level of detail to the discussion.

2. Commas are overused in several places in the manuscript

3. "Hand-searched" is an odd term - were the hands actually used to search? Or are you indicating that the references were individually reviewed by the authors?

4. It is generally frowned upon to refer to patients by only the noun "smokers" (line 114) instead of "patients who were active smokers" or "patients who smoke".

5. Its confusing to the readers how RCTs would address barriers/facilitators in the methods section, though clarified later when it is stated that they had additional qualitative analysis performed.

6. were the 10 pilot screening references chosen at random? Or were they the first (and likely most relevant) 10?

7. Please provide more detail about Covidence (company, location is usually appropriate when referring to a software in a scientific manuscript)

8. Do not repeat data that is in tables in text (including location of studies). This will help with the referenced word limits in response to other reviewer comments.

9. Table 2 - "physicians and surgeons should provide advice to quit smoking..." how is a "should" statement a facilitator? Do you mean that if they BOTH did it it was a facilitator? It's confusing.

10. How are perceived health benefits a barrier - does that mean "lack of" perceived benefits?

11. Knowledge "on" is used often - do they mean knowledge of?

12. Why is 8: lack of intention - "providers' belief.." not in the belief section?

13. In the discussion authors state (line 233) that there is a "misconception" that interventions were not efficacious - in fact recent systematic reviews have supported this conception.

14. Must of the discussion is biased in statements that interventions help but not supported by the data - for example line 301-302 reports on beliefs but lacks robust data as to actual outcomes.

15. Similarly in lines 388-390

16. Overall discussion rehashes much of the results without substantial additional information - would be helpfful to make more concise and summarize what of your results is new/additive to the literature in each area.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Jun 11;19(6):e0298233. doi: 10.1371/journal.pone.0298233.r006

Author response to Decision Letter 2


23 Nov 2023

We have included a "Response to Reviewers" document wherein we have addressed all comments. Thank you.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0298233.s008.docx (55.7KB, docx)

Decision Letter 3

Silvia Fiorelli

22 Jan 2024

Barriers and facilitators to perioperative smoking cessation: a scoping review

PONE-D-23-16365R3

Dear Dr. OFORI,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Silvia Fiorelli

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Congratulations to the authors and thanks to the reviewers for the provided suggestions which really helped improve the quality of the manuscript

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #4: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #4: Thank you for the detailed responses. Improved with appropriate edits.

Trying to meet minimum character count.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #4: No

**********

Acceptance letter

Silvia Fiorelli

21 Feb 2024

PONE-D-23-16365R3

PLOS ONE

Dear Dr. OFORI,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Silvia Fiorelli

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Number of barriers and facilitators mapped to each TDF domain.

    (DOCX)

    pone.0298233.s001.docx (29.8KB, docx)
    S1 Table. Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist.

    (DOCX)

    pone.0298233.s002.docx (26.4KB, docx)
    S2 Table. Search strategies.

    (DOCX)

    pone.0298233.s003.docx (26.7KB, docx)
    S3 Table. Quality assessment of included studies with the Mixed Methods Appraisal Tool (MMAT).

    (DOCX)

    pone.0298233.s004.docx (19.8KB, docx)
    S1 File. Reports excluded at full text screening stage.

    (DOCX)

    pone.0298233.s005.docx (24.8KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0298233.s006.docx (22.8KB, docx)
    Attachment

    Submitted filename: RESPONSE TO REVIEWER.docx

    pone.0298233.s007.docx (70KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0298233.s008.docx (55.7KB, docx)

    Data Availability Statement

    All data files are available from the Open science Framework (OSF) database: https://osf.io/z3pyd/?view_only=c621853d3da0494082da159907058be6.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES